Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target of $25.00.
Jason McCarthy has given his Buy rating due to a combination of factors surrounding Capricor Therapeutics’ promising developments. The company’s lead therapy, Deramiocel, is in late-stage clinical trials for treating Duchenne muscular dystrophy (DMD) cardiomyopathy and has been granted priority review by the FDA, with a PDUFA date set for August 31, 2025. The potential approval of Deramiocel could bring significant financial benefits, including an $80 million milestone payment from their partner Nippon and a Priority Review Voucher, which could be monetized for substantial revenue.
Additionally, Capricor’s strong financial position, with $151.5 million in cash, provides a runway into 2027, supporting ongoing and future developments. The company is actively preparing for the commercial launch of Deramiocel, with manufacturing capacity expansions underway to meet anticipated demand. The strategic partnership with Nippon Shinyaku for commercialization in the US, Japan, and the EU further strengthens Capricor’s market position, with potential milestone payments totaling approximately $1.5 billion. These factors collectively underpin McCarthy’s optimistic outlook and Buy rating for Capricor Therapeutics.
In another report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $30.00 price target.
CAPR’s price has also changed dramatically for the past six months – from $5.050 to $14.360, which is a 184.36% increase.